



October 7, 2021

BSE Limited Corporate Relationship DepartmentPhiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

Scrip Code: 500456

Sub: Revision in Credit Rating for bank facilities

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We wish to inform you that Credit Rating Agency - CARE has revised the credit rating in respect of bank facilities availed by the Company and upgraded rating from BBB+/Stable to BBB+/Positive outlook for long term bank facilities and re-affirmed rating CARE A2 for short term bank facilities.

We are enclosing herewith copy of letter No. CARE/DRO/RL/2021-22/2305 dated 01.10.2021, as received from CARE, in respect of credit rating assigned to bank facilities of the Company.

Please take the same in your records.

Thanking you,

Yours faithfully,

For Pasupati Acrylon Limited

Bharat Kapoor

Company Secretary & Compliance Officer

Encl: as above

PASUPATI ACRYLON LTD

□ CORPORATE OFFICE: M-14, CONNAUGHT CIRCUS (MIDDLE CIRCLE), NEW DELHI-110 001 (INDIA) □ PHONE: EPABX- 47627400 □ Fax: 91-11-47627497, 47627498 □ E-MAIL: delhi@pasupatiacrylon.com □ VISIT OUR SITE: http://www.pasupatiacrylon.com

□ REGD. OFFICE & WORKS : KASHIPUR ROAD, THAKURDWARA- 244 601, DISTT. MORADABAD (U.P.)

☐ E-MAIL : works@pasupatiacrylon.com • pasupati_tkd@rediffmail.com

☐ CIN: L50102UP1982PLC015532



No. CARE/DRO/RL/2021-22/2305

Shri Vineet Jain
Managing Director
Pasupati Acrylon Limited
M-14, Connaught Place
New Delhi-110001

October 01, 2021

Confidential

Dear Sir,

Credit rating for bank facilities

On the basis of recent developments including operational and financial performance of your company for FY21 (Audited) and Q1FY22, our Rating Committee has reviewed the following ratings:

Facilities	Amount (Rs. crore)	Rating¹ Rating Δct		
Lana Tarra Dank		CARE BBB+; Positive	Reaffirmed;	
Long Term Bank	10.62	(Triple B Plus; Outlook:	Outlook revised	
Facilities		Positive)	from Stable	
Short Term Bank	280.00	CARE A2	D (("	
Facilities	(Enhanced from 155.00)	(A Two)	Reaffirmed	
	290.62			
Total Facilities	(Rs. Two Hundred Ninety Crore			
	and Sixty-Two Lakhs Only)			

- 2. Refer **Annexure 1** for details of rated facilities.
- 3. The rationale for the rating will be communicated to you separately. A write-up (press release) on the above rating is proposed to be issued to the press shortly, a draft of which is enclosed for your perusal as **Annexure 2**. We request you to peruse the annexed document and offer your comments if any. We are doing this as a matter of courtesy to our clients and with a view to ensure that no factual inaccuracies have inadvertently crept in. Kindly revert as early as possible. In any case, if we do not hear from you by **October 04, 2021**; we will proceed on the basis that you have no any comments to offer.
- 4. CARE reserves the right to undertake a surveillance/review of the rating from time to time, based on circumstances warranting such review, subject to at least one such review/surveillance every year.

¹Complete definitions of the ratings assigned are available at <u>www.careratings.com</u> and in other CARE publications.

5. CARE reserves the right to revise/ reaffirm /withdraws the rating assigned as also revise the outlook, as a result of periodic review/surveillance, based on any event or information which in the opinion of CARE warrants such an action. In the event of failure on the part of the entity to furnish such information, material or clarifications as may be required by CARE so as to enable it to carry out continuous monitoring of the rating of the bank facilities, CARE shall carry out the review on the basis of best available information throughout the life time of such bank facilities. In such cases the credit rating symbol shall be accompanied by "ISSUER NOT COOPERATING". CARE shall also be entitled to publicize/disseminate all the afore-mentioned rating actions in any manner considered appropriate by it, without reference to you.

6. CARE ratings do not take into account the sovereign risk, if any, attached to the foreign currency loans, and the ratings are applicable only to the rupee equivalent of these loans.

7. Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.

8. Users of this rating may kindly refer our website www.careratings.com for latest update on the outstanding rating.

9. CARE ratings are **not** recommendations to sanction, renew, disburse or recall any bank facilities. If you need any clarification, you are welcome to approach us in this regard.

Thanking you, Yours faithfully,

Karishma Badhwar

Analyst

karishma.badhwar@careratings.com

Amit Jindal

Assistant Director

amit.jindal@careratings.com

Encl.: As above

Disclaimer

CARE's ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE's ratings do not convey suitability or price for the investor. CARE's ratings do not constitute an audit on the rated entity. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE or its subsidiaries/associates may also have other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating /outlook assigned by CARE is, inter-alia, based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors. CARE is not responsible for any errors and states that it has no financial liability whatsoever to the users of CARE's rating.

Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.

Annexure 1

Details of Rated Facilities

1. Long Term Facilities

1.A. Fund Based Limits

Sr. No.	Name of Bank / Lender	Rated Amount (Rs. crore)	Remarks
1.	Indian Bank	3.36	
2.	State Bank of India	3.16	
3.	UCO Bank	1.68	Cash Credit
4.	Bank of Maharashtra	0.96	Cash Credit
5.	Bank of Baroda	0.90	
6.	Canara Bank	0.56	
	Total	10.62	

Total Long-Term Facilities: Rs.10.62 crore

2. Short Term Facilities

2.A. Non-Fund Based Limits

Sr. No.	Name of Bank / Lender	Rated Amount (Rs. crore)	Remarks
1.	Indian Bank	49.05	
2.	State Bank of India	46.16	
3.	UCO Bank	24.52	
4.	Bank of Maharashtra	13.98	BG/LC
5.	Bank of Baroda	13.13	
6.	Canara Bank	8.16	
7.	Proposed	125.00	
	Total	280.00	

Total Short-Term Facilities: Rs.280.00 crore

Total Facilities (1. A+2.A): Rs.290.62 crore

Annexure - II Press Release Pasupati Acrylon Limited

Ratings

Facilities/Instruments	Amount (Rs. crore)	Rating ¹	Rating Action
Long Term Bank Facilities	10.62	CARE BBB+; Positive (Triple B Plus; Outlook: Positive)	Reaffirmed; Outlook revised from Stable
Short Term Bank Facilities	280.00 (Enhanced from 155.00)	CARE A2 (A Two)	Reaffirmed
Total Bank Facilities Total Bank Facilities (Rs. Two Hundre Ninety Crore and Si Two Lakhs Only			

Details of instruments/facilities in Annexure-1

Detailed Rationale and key rating drivers

The ratings to the bank facilities of Pasupati Acrylon Limited (PAL) continues to derive strength from the established position of the company over three decades in acrylic staple fibre (ASF) industry, experienced promoters and management team, established relationship with customer and suppliers. The rating also factors PAL's foray in Cast Polypropylene (CPP) film segment leading to revenue diversification and comfortable financial risk profile.

The ratings are, however, constrained on account of working capital-intensive operations, foreign exchange, raw material volatility and availability of cheaper substitutes.

Outlook: Positive

CARE has revised the outlook from stable to positive considering the improvement in profitability margins, debt protection metrics, strong liquidity position and comfortable operating cycle. The outlook shall be revised to 'Stable' if the company is unable to sustain its existing profitability margins owing to volatility in raw material prices. Further, ratings may be revised upward in case there is overall improvement in operational performance of the company alongside sustaining its profitability margins.

Key Rating Sensitivity

Positive Factors

- Sustained increase in total operating income beyond Rs 900 crore.
- Sustaining the improvement in the PBILDT margins at 13%.

Negative Factors

- Increase in overall gearing (including acceptance) beyond 1x.
- Decline in PBILDT Margins below 3% on sustained basis.

Detailed description of the key rating drivers

Key Rating Strengths

Established position in acrylic fibre industry

Pasupati Acrylon Limited (PAL) was established in 1982 and is a leading manufacturer of Acrylic Staple Fibre (ASF). However, it started its commercial operation in 1990. It is engaged in manufacturing of Acrylic Staple Fibre (ASF), both in dyed & grey form and has further diversified in Cast Polyproylene film (CPP). The domestic ASF

¹Complete definition of the ratings assigned are available at <u>www.careratings.com</u> and other CARE publications CARE Ratings Ltd.

industry is mainly concentrated among three large manufacturers namely PAL, Vardhman Acrylic Limited and Indian Acrylics Limited. PAL is one of the largest acrylic producers in the country with 42,000 Metric Tonnes Per Annum (MTPA).

Experienced promoter and Management team

Pasupati Acrylon Limited was promoted in 1982 by Mr. Vineet Jain, Managing Director. Mr. Jain is BBA (London) and has been associated with PAL since 1990. He has around three decades of experience in the acrylic industry. Mr. S. P. Gupta is the Director of Operation who has a B. Tech in Chemical Engineering and has been associated with PAL since 2012. He has previously worked with various industries such as Acrylic Fibre, Chemicals, Fertilizer, Tea etc. and has got over four decades of experience. The promoters are supported by professional management team who have relevant experience in the industry.

Established relationship with customers & suppliers over the years

Due to the its long track record of operations, PAL has developed an established relationship with its customers and suppliers. The company has been dealing with customers since last 25 years thus has been getting repeat orders from them. The revenue profile of the company is fairly diversified in terms of customers as top 10 customers contributed around 48% of sales during FY21 vis-à-vis 44% in FY20.

Comfortable financial risk profile

The total operating income of the company has declined by 31% to Rs. 511.41 crore in FY21 as against Rs. 667.65 crore in FY20 mainly on account of lower demand as a result of business operations being adversely affected by Covid-19 pandemic. The sales volume of ASF has declined by 19% to 31,361 metric tonne (MT) in FY21 (PY: 38,771 MT) along with decline in sales realization by 7% to Rs. 145.47/kg (PY: Rs. 156.36/kg). Further, sales volume of CPP also decreased by 12% to 3,898 MT (PY: 4,420 MT) though sales realization increased by 4% to Rs. 126.30/kg in FY21 from Rs. 121.40/kg in FY20. During Q1FY22 (Prov results: refer to the period from April 01 to June 30), the company has achieved sales of Rs. 123.77 crore.

The PBILDT margins improved by 843 bps to 12.86% in FY21 from 4.43% in FY20 and PAT margin increased to 8.42% in FY21 from 1.95% in FY20. The raw materials for ASF is majorly imported and has an average lead time of 5 months between buying and selling process. The raw material price (ACN) was low when order for the same was placed. Thus, the company benefitted from it as prices of ASF went up mimicking price movements of ACN in the last two quarter of FY21 and Q1FY22. The PBILDT and PAT margin stood at 19.93% and 13.44% respectively in Q1FY22.

The overall gearing has improved to 0.42x as on March 31, 2021 from 0.58x as on March 31, 2020 account of higher networth base resulting from accretion of profit to reserves. Further, the debt protection metrics as marked by interest coverage and TDGCA also improved owing to better profitability. Interest coverage ratio stood at 17.41x for FY21 as against 5.93x for FY20 while TDGCA stood at 1.99x for FY21 as against 5.23x for FY20. For Q1FY22, interest coverage ratio stood at 36.28x.

Foray in flexible packing industry would provide revenue diversification and growth

The company has diversified into CPP Film (flexible packaging) by starting commercial operations in Sep, 2017 and had set up manufacturing capacity of 5,000 MTPA then. Further, the company had implemented expansion of CPP Films by another 5000 MT, taking total production capacity to 10000 MT.. The flexible packaging industry has been growing at a healthy rate and finds application in industries such as snacks, confectioneries, tobacco, spices etc. The company reported income of Rs. 49.23 crore during FY21 from CPP Films vis-à-vis Rs 53.66 crore in FY20.

Key Rating Weaknesses

Volatility in profitability due to raw material and foreign exchange fluctuations

PAL's profitability margins have remained volatile in the past primarily on account of raw material being crude derivative and the prices are dollar denominated. Acrylonitrile (ACN) the major raw material (~72% of total cost in FY21) being a derivative of crude demonstrates volatility. ACN cost reduced to Rs. 97.47/kg in FY21 from Rs. 112.52/kg in FY20. The prices get impacted with fluctuation in crude oil as well as the USD rates. Inability to pass on increase in the raw material cost might have adverse impact on the profitability of the company. The company

imports majority of raw material consumed (around 85% in FY21) from USA, Japan etc. and thus is also exposed to foreign exchange fluctuation risk. The risk is mitigated to some extent as the company derives around 17% in FY21 (PY: 28%) of its revenue from exports thereby providing it natural hedge to that extent. Further, as per risk management policy of PAL, foreign currency fluctuation risk is managed through limited and short-term hedging of transaction with bankers. The company normally hedges its exposure for the next two months in advance and as on Sep 20, 2021 the company has hedged its exposure of LC payment due till November 2021. Nevertheless, the company is exposed to the foreign exchange fluctuation risk.

High inventory holding

The operations of the company are working capital intensive as the company holds inventory of around 92 days in FY21 as against 58 days in FY20. The increase in inventory days is owing to decline in sales as the inventory in absolute terms has remained almost in line with the previous year. The raw material acrylonitrile is 100% imported and it takes around 5 months between the shipment of the raw material and the point of sale of the product acrylic stable fiber.

The average collection days for the company has remained around 32 days in FY21 as the company provides 15-30 days credit to its domestic customers while certain customer makes advance payment. The export receivables are either backed by advances or LC (which is discounted). Also, the company purchases its raw material on LC thereby getting a credit of around 90-180 days. The average creditor days remained around 90 days during FY21 as against 74 days in FY20. Entailing all, operating cycle increased to 34 days in FY21 from 12 days in FY20.

Competitive industry scenario with cheaper substitutes and imports

Acrylic is a substitute for cotton, wool and polyester and thus faces intense competition from these substitutes. Furthermore, the industry also faces competition from imports due to demand supply mismatch and capacities. The domestic acrylic industry is concentrated among few players and the major raw material ACN has high volatility. However, as the prices are set on monthly basis, considering the current raw material prices, import prices and exchange rate, thereby reducing the competition to certain extent.

Liquidity analysis: Strong- Liquidity is marked by strong accruals of Rs 49.59 crore in FY21 and envisaged GCA of Rs. 33.20 crore in FY22 against negligible repayment obligations of Rs 0.06 crore and liquid investments to the tune of Rs. 68.76 crore as on March 31, 2021. With a gearing of 0.42 times as of March 31, 2021, the issuer has sufficient gearing headroom, to raise additional debt for its capex. Its unutilized bank lines are more than adequate to meet its incremental working capital needs over the next one year.

Analytical Approach: Standalone

Applicable Criteria

Criteria on assigning Outlook to Credit Ratings

CARE's Policy on Default Recognition

Criteria for Short Term Instruments

Rating Methodology for Manmade Yarn Manufacturing Sector

Rating Methodology - Manufacturing Companies

Liquidity Analysis of Non-Financial Sector entities

Financial ratios - Non-Financial Sector

About the Company

Pasupati Acrylon Limited (PAL), promoted by Mr. Vineet Jain, is engaged in manufacture of Acrylic Staple Fibre (ASF), both in dyed & grey form. PAL has a manufacturing plant located at Moradabad District (Uttar Pradesh) with installed capacity of 42,000 Metric Tonnes Per Annum (MTPA) and is one of the largest domestic acrylic producers. The company has also diversified into CPP Film (flexible packaging) and has set up manufacturing capacity of 10,000 MTPA which started commercial operations since September, 2017.

(Rs. In crore)

Brief Financials (Rs. crore)	FY19	FY20	FY21
	Α	Α	Α
Total operating income	831.58	667.65	511.41
PBILDT	53.97	29.60	65.74
PAT	27.38	13.05	43.05
Overall gearing (times)	0.77	0.58	0.42
Interest coverage (times)	6.61	5.93	17.41

A-Audited

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable.

Rating History (Last three years): Please refer Annexure-2

Covenants of rated instrument / facility: Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

Complexity level of various instruments rated for this company: Annexure 4

Annexure-1: Details of Instruments/Facilities

Name of the Instrument	ISIN	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. crore)	Rating assigned along with Rating Outlook
Fund-based - LT- Cash Credit		-	-	1	10.62	CARE BBB+; Positive
Non-fund-based - ST-BG/LC		-	-	-	280.00	CARE A2

Annexure-2: Rating History of last three years

		Current Ratings				Rating history			
Sr. No.	Name of the Instrument/Bank Facilities	Туре	Amount Outstanding (Rs. crore)	Rating	Date(s) & Rating(s) assigned in 2021- 2022	Date(s) & Rating(s) assigned in 2020- 2021	Date(s) & Rating(s) assigned in 2019- 2020	Date(s) & Rating(s) assigned in 2018- 2019	
1	Fund-based - LT- Cash Credit	LT	10.62	CARE BBB+; Positive	-	1)CARE BBB+; Stable (01-Dec- 20)	1)CARE BBB+; Stable (03- Jan- 20)2)CARE BBB+; Stable (05- Apr-19)	1)CARE BBB+; Stable (01- Oct- 18)2)CARE BBB+; Stable (06- Sep- 18)3)CARE BBB+; Stable (02- Apr-18)	

2	Non-fund-based - ST-BG/LC	ST	280.00	CARE A2	-	1)CARE A2 (01- Dec-20)	1)CARE A2 (03-Jan- 20)2)CARE A2 (05- Apr-19)	1)CARE A2 (01-Oct- 18)2)CARE A2 (06- Sep- 18)3)CARE A2 (02- Apr-18)
3	Fund-based - LT- Term Loan	-	-	-	-	-	1)CARE BBB+; Stable (05- Apr-19)	1)CARE BBB+; Stable (01- Oct- 18)2)CARE BBB+; Stable (06- Sep- 18)3)CARE BBB+; Stable (02- Apr-18)

Annexure-3: Detailed explanation of covenants of the rated instrument / facilities: Not Applicable

Annexure 4: Complexity level of various instruments rated for this Company

Sr. No	Name of instrument	Complexity level
1	Fund-based - LT-Cash Credit	Simple
2	Non-fund-based - ST-BG/LC	Simple

Note on complexity levels of the rated instrument: CARE has classified instruments rated by it on the basis of complexity. This classification is available at www.careratings.com. Investors/market intermediaries/regulators or others are welcome to write to care@careratings.com for any clarifications

Contact us

Media Contact

Mr. Mradul Mishra

Contact no.: +91-22-6837 4424

Email ID: <u>mradul.mishra@careratings.com</u>

Analyst Contact

Mr. Amit Jindal

Contact no.: +91- 11-4533 3228 Email ID: <u>amit.jindal@careratings.com</u>

Relationship Contact

Ms. Swati Agrawal

Contact no.: +91-11-4533 3200

Email ID: swati.agrawal@careratings.com

About CARE Ratings:

CARE Ratings commenced operations in April 1993 and over two decades, it has established itself as one of the leading credit rating agencies in India. CARE is registered with the Securities and Exchange Board of India (SEBI) and also recognized as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). CARE Ratings is proud of its rightful place in the Indian capital market built around investor confidence. CARE Ratings provides the entire spectrum of credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an informed investment

decision based on the credit risk and their own risk-return expectations. Our rating and grading service offerings leverage our domain and analytical expertise backed by the methodologies congruent with the international best practices.

Disclaimer

CARE's ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE's ratings do not convey suitability or price for the investor. CARE's ratings do not constitute an audit on the rated entity. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE or its subsidiaries/associates may also have other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating /outlook assigned by CARE is, inter-alia, based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors. CARE is not responsible for any errors and states that it has no financial liability whatsoever to the users of CARE's rating.

Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.

**For detailed Rationale Report and subscription information, please contact us at www.careratings.com